Weight Reduction in PCOS: Causes and Treatments

Weight reduction in PCOS is a common challenge, affecting many people with polycystic ovary syndrome due to the complex interplay of insulin resistance, hormonal imbalance and metabolic dysfunction. Unlike typical weight management, PCOS creates a self-reinforcing cycle where elevated insulin and androgens make fat loss considerably harder. This article explores why losing weight with PCOS is so difficult, which medications and lifestyle strategies have the strongest evidence, and when to seek specialist support from your GP or a multidisciplinary team.

Why is losing weight so difficult with PCOS?

Insulin resistance is the primary reason weight reduction in PCOS is harder than usual, driving fat storage, raising androgen levels and disrupting appetite hormones, creating a self-reinforcing cycle that standard diet advice alone cannot break.

Weight reduction in PCOS is harder than in the general population primarily because of insulin resistance, which is common in people with the condition and drives both weight gain and difficulty losing it.^[1][2] Polycystic ovary syndrome (PCOS) is a hormonal condition characterised by elevated androgens, irregular ovulation and, in many cases, metabolic dysfunction. Insulin resistance means the body produces more insulin than usual to keep blood glucose stable, and raised insulin levels promote fat storage, particularly around the abdomen, while also stimulating further androgen production.

This creates a self-reinforcing cycle: higher androgens worsen insulin resistance, which in turn makes weight management more difficult and can intensify symptoms such as irregular periods, acne and excess hair growth. Appetite-regulating hormones, including leptin and ghrelin, are also disrupted in some people with PCOS, meaning hunger signals may not function normally, making calorie restriction feel considerably harder than it would otherwise.^[6]

Psychological factors compound the physical ones. Studies have consistently shown higher rates of anxiety, depression and disordered eating in people with PCOS, all of which can undermine sustained lifestyle change.^[1][7] Fatigue related to poor sleep, which is more common in PCOS, further reduces motivation and physical activity capacity. If you experience symptoms such as loud snoring or excessive daytime sleepiness, mention these to your GP, as sleep disturbance in PCOS can sometimes be linked to obstructive sleep apnoea.

Understanding these biological and psychological barriers is important because it means that standard advice to simply eat less and move more is rarely sufficient on its own, and a more targeted, multidisciplinary approach is usually needed. The NICE Clinical Knowledge Summary on PCOS and the NHS PCOS overview provide further detail on these mechanisms and their clinical implications.

Which treatments and medications can support weight loss in PCOS?

GLP-1 receptor agonists such as semaglutide and tirzepatide, and metformin for insulin resistance, are the main medicines used to support weight loss in PCOS, though all require prescriber assessment as no medicine is licensed specifically for PCOS-related weight gain.

Several medications can support weight reduction in PCOS, though the appropriate choice depends on individual clinical circumstances and should always be guided by a qualified prescriber. No single medicine is licensed specifically for PCOS-related weight gain, but several are used within this context. The examples below are not exhaustive; your prescriber can advise on all available options.

Metformin is widely used off-label in PCOS to improve insulin sensitivity, particularly in people with metabolic features such as impaired glucose regulation or higher BMI. NICE Clinical Knowledge Summary on PCOS and the international evidence-based PCOS guideline (Monash/ESHRE/ASRM, 2023 update) acknowledge its role in managing metabolic features of the condition. It may modestly support weight management by reducing insulin-driven fat storage, though it is not a primary weight-loss medicine.

GLP-1 receptor agonists have become increasingly relevant. Liraglutide (Saxenda) is MHRA-authorised for chronic weight management in adults with a BMI of 30 kg/m² or above (or 27 kg/m² with a weight-related comorbidity).^[17][18] Semaglutide (Wegovy) is similarly authorised; the subcutaneous injection is available in a maintenance regimen of up to 2.4 mg weekly, and a higher-dose 7.2 mg weekly regimen is also authorised in the UK. Exact posology for each regimen should be verified against the relevant UK SmPC. An oral formulation of semaglutide for weight management (Wegovy 25 mg tablets) received MHRA approval in June 2026 and has a different licensed posology from the injection; consult the UK SmPC for details.^[15][16] Orlistat is another MHRA-authorised option for weight management and may be considered where appropriate. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, is MHRA-authorised both for type 2 diabetes and for chronic weight management.^[20][21] These medicines work by slowing gastric emptying, reducing appetite and improving insulin sensitivity, all of which are particularly relevant in PCOS.

Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, a GPhC-registered UK online pharmacy, and is only prescribed where it is clinically appropriate.

Pregnancy and breastfeeding: Weight-management medicines including liraglutide, semaglutide and tirzepatide are not recommended during pregnancy or breastfeeding. If you are planning a pregnancy, discuss discontinuation timing with your prescriber well in advance; the required washout period differs between medicines and is set out in section 4.6 of each UK SmPC. Use effective contraception while taking these medicines.

Women of childbearing potential using Mounjaro should note that the UK SmPC advises using an additional non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase, as gastrointestinal effects may reduce oral contraceptive absorption.^[23]

Eligibility for NHS-funded weight-management medicines is determined locally by Integrated Care Boards (ICBs), and access criteria vary.

What diet and lifestyle changes actually work for PCOS weight management?

A low-GI diet combined with at least 150 minutes of moderate aerobic activity and two resistance training sessions per week is the most evidence-supported approach, directly targeting the insulin resistance underlying PCOS.

A low-glycaemic index (GI) diet is among the most evidence-supported dietary approaches for weight reduction in PCOS, as it directly addresses the insulin resistance that underlies much of the condition's metabolic dysfunction.^[9][7] Low-GI foods release glucose more slowly, blunting the insulin spikes that promote fat storage and androgen production. Practical examples include oats, legumes, non-starchy vegetables and wholegrains in place of refined carbohydrates and sugary foods. Evidence for this approach in PCOS comes from systematic reviews and is reflected in the international PCOS guideline (Monash/ESHRE/ASRM, 2023 update) and the British Dietetic Association (BDA) PCOS Food Factsheet.

Calorie deficit remains necessary for weight loss, but the composition of the diet matters in PCOS. Higher protein intakes can improve satiety and help preserve lean muscle mass during weight loss; the specific proportion that suits you is best discussed with a registered dietitian, as individual needs vary. Anti-inflammatory dietary patterns, such as a Mediterranean-style diet rich in oily fish, olive oil, nuts and vegetables, have shown benefit in small trials by reducing both systemic inflammation and androgen levels, though the evidence base remains limited.^[10][7]

If you have a history of disordered eating, speak to your GP or a dietitian before making significant dietary changes, so that any nutritional plan can be tailored safely.

Physical activity recommendations for PCOS align broadly with the UK Chief Medical Officers' guidelines of at least 150 minutes of moderate-intensity aerobic activity per week, combined with two sessions of resistance training.^[24][25] Resistance exercise is particularly valuable in PCOS because it improves insulin sensitivity independently of weight loss and helps maintain muscle mass.^[26][27] High-intensity interval training (HIIT) has also shown promising results in small studies.

Behavioural support is a key component. NICE guidance on obesity recommends structured behavioural interventions as part of any weight-management programme; check the current NICE obesity guideline for the most up-to-date recommendations. Cognitive behavioural therapy (CBT) and mindfulness-based approaches can help address emotional eating and the psychological burden of PCOS. Even modest weight loss of 5 to 10% of body weight has been shown in clinical studies to improve menstrual regularity, fertility outcomes and metabolic markers in people with PCOS.

When should you speak to a GP or specialist about PCOS and weight?

See your GP if lifestyle changes have not produced meaningful results after three to six months, or if symptoms such as irregular periods, fertility difficulties or metabolic concerns are worsening despite consistent effort.

You should speak to your GP about PCOS and weight if lifestyle changes have not produced meaningful results after three to six months of consistent effort, or if your symptoms, including irregular periods, fertility difficulties or metabolic concerns, are worsening despite your efforts. A GP can arrange relevant investigations, including fasting glucose, HbA1c, lipid profile, and hormone levels, to build a clearer picture of your metabolic health and guide treatment decisions. Depending on your circumstances, your GP may also check thyroid function (TSH) or prolactin, or arrange an oral glucose tolerance test (OGTT), for example if HbA1c is borderline or you are planning a pregnancy. These decisions are guided by NICE Clinical Knowledge Summary on PCOS and local primary care protocols.

If you develop symptoms that could suggest rapid or severe virilisation (for example, very sudden or marked deepening of the voice, significant clitoral enlargement, or features that might suggest Cushing's syndrome such as central weight gain with easy bruising and stretch marks), seek prompt medical review, as these may indicate a cause other than PCOS requiring urgent investigation.

Referral to a specialist may be appropriate in several circumstances:

• Endocrinology or gynaecology if PCOS symptoms are severe, diagnosis is uncertain, or hormonal management needs review

• Dietetics for personalised nutritional support, particularly if disordered eating is a concern

• Fertility services if conception is a goal and weight or hormonal factors are affecting ovulation

• Tier 3 weight-management services if BMI and comorbidities meet local ICB criteria for specialist input

If you experience symptoms that may suggest complications, such as signs of type 2 diabetes (increased thirst, frequent urination, unexplained fatigue) or cardiovascular symptoms, contact your GP promptly. For urgent symptoms such as chest pain or severe breathlessness, call 999 or go to A&E. For non-emergency medical advice outside GP hours, NHS 111 is available.

If you are taking any weight-management medicine and experience a suspected side effect, this can be reported to the MHRA via the Yellow Card scheme at https://yellowcard.mhra.gov.uk/. Any new or worsening symptoms, including persistent abdominal pain (which may rarely indicate pancreatitis), should be discussed with your prescriber or GP without delay.

Scientific References

1. Polycystic ovary syndrome (Teede HJ et al., Lancet Diabetes & Endocrinology).
2. Recent advances in reprogramming lactate metabolism in polycystic ovary syndrome (Journal of Ovarian Research).
3. Effect of High Fat Diet on Disease Development of Polycystic Ovary Syndrome and Lifestyle Intervention Strategies (Nutrients).
4. Insulin signaling in PCOS/PMOS: molecular insights and clinical implications (Frontiers in Endocrinology).
5. Physical activity, sedentary behavior, and metabolic-reproductive health in women with PMOS (PCOS): a narrative review (Frontiers in Endocrinology).
6. Ghrelin and measures of satiety are altered in polycystic ovary syndrome.
7. The Role of Lifestyle Interventions in PCOS Management: A Systematic Review (Nutrients).
8. Ranking the dietary interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis (Reproductive Health).
9. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Frontiers in Endocrinology).
10. Dietary interventions for modulating the gut microbiome in PCOS management (Frontiers in Endocrinology).
11. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
12. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
13. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (Novo Nordisk).
14. Wegovy 7.2 mg Solution for injection in pre-filled pen – Summary of Product Characteristics (Novo Nordisk).
15. First GLP-1 tablet for weight loss approved in the UK.
16. Wegovy – CHMP post-authorisation summary of positive opinion (oral semaglutide indication).
17. Saxenda – European Public Assessment Report.
18. Liraglutide – Drugs – BNF.
19. Liraglutide Biocon 6 mg/ml solution for injection in pre-filled pen – Summary of Product Characteristics (Biocon Pharma UK Limited).
20. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
21. Tirzepatide – NHS medicines information.
22. Tirzepatide – Drugs – BNF.
23. Tirzepatide – Interactions – BNF.
24. UK Chief Medical Officers' physical activity guidelines.
25. Physical activity guidelines for adults aged 19 to 64.
26. Metabolic Stress Testing Reveals Persistent Lipid-Handling Dysfunction in Women With Polycystic Ovary Syndrome Despite Exercise Training (Diabetes, Obesity & Metabolism).
27. The effect of high intensity interval training on free androgen index in patients with polycystic ovary syndrome (BMC Endocrine Disorders).
28. Effect of Exercise Therapy on Non-Obese Women with Polycystic Ovary Syndrome: A Protocol for a Randomized Controlled Trial (Complementary Medicine Research).

Frequently Asked Questions